BridGene Biosciences, a leader in the discovery and development of small molecule drugs for traditionally 'hard-to-drug' targets, today announced the recent completion of a $28 million Series B+ financing round. The round was led by Bayland Capital, with participation from GTJA Investment Group, Proxima Ventures, and existing investors Lapam Capital and Grains Valley Venture Capital.

BridGene Biosciences is a biotechnology company pioneering the discovery and development of innovative small-molecule drugs that target traditionally undruggable targets. Leveraging its proprietary IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) chemoproteomic platform, BridGene screens covalent small molecules against the entire proteome in live cells to identify novel binding sites and drug candidates for high-value targets.

The company is advancing a diversified pipeline led by BGC-515, a covalent TEAD inhibitor currently in clinical development for solid tumors, along with additional programs in oncology and autoimmune diseases. BridGene's approach integrates deep chemical biology with translational insight to unlock new therapeutic opportunities and bring transformative medicines to patients.